Construction of anti-tumor immune gene signature for HNSCC and identification of 4'-Hydroxywogonin as a potential immunotherapy combination drug
This study successfully constructed a robust gene signature ATIGS, as well as identified a potential immunotherapy combination drug 4'-Hydroxywogonin. The ATIGS could effectively predict the prognosis and immunotherapy response of HNSCC patients, which may contribute towards enriching the immunotherapy-responsive population and enhancing the clinical efficacy of immunotherapy. Meanwhile, 4'-Hydroxywogonin may provide a promising clinical treatment strategy.
Authors
- Weihong Ge
- Weijie Qiang (ORCID: https://orcid.org/0000-0001-5497-7800)
- Yifei Dai (ORCID: https://orcid.org/0000-0003-1691-6884)
- Lele Wang (ORCID: https://orcid.org/0009-0008-3006-313X)
- Jianjun Wang (ORCID: https://orcid.org/0000-0003-3375-8179)
Institutions
- China Pharmaceutical University (CN)
- Nanjing Drum Tower Hospital (CN)
- Shanghai East Hospital (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1186/s12935-025-03910-y
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation